EU Regulatory Roundup, October 2018: Regs 'On Track,' First NB Designations On Way, While UK Prepares For No-Deal Brexit
Executive Summary
The European Commission has been much more vocal this month. Its message is upbeat. Despite what industry is saying about delays, logjams and products being forced off the market, it claims to be "on track" for timely implementation of the EU's new Medical Device and IVD Regulations. That and more, in top EU regulation stories from October.
You may also be interested in...
Helping Hand: A Guide To The New UK Consultations On No-Deal Brexit Regs
With just over three weeks to provide input on the UK's proposed regulatory response to the prospect of a no-deal Brexit, Medtech Insight unravels key messages from the four documents issued by the Medicines and Healthcare products Regulatory Agency (MHRA), condensing 127 pages into the main points to aid industry in providing feedback. There's no time to waste for those wishing to influence the outcome.
EU Regulatory Experts Support Notified Bodies, But Argue For Greater Consistency
Notified bodies have been a pivotal part of the EU medtech regulatory system since it was first launched in the 1990s. Where might they fit within a new medtech regulatory governance structure? Panelists on a recent vodcast grappled with the question.
First Public Discussion On How EU Medtech Regulatory Governance Structure May Evolve
Does the EU need a medtech agency for the first time in its history? Nothing can or should be decided too quickly but five high-profile experts broadly agreed that change is now critical.